Your browser doesn't support javascript.
loading
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.
van den Bent, Martin J; Baumert, Brigitta; Erridge, Sara C; Vogelbaum, Michael A; Nowak, Anna K; Sanson, Marc; Brandes, Alba Ariela; Clement, Paul M; Baurain, Jean Francais; Mason, Warren P; Wheeler, Helen; Chinot, Olivier L; Gill, Sanjeev; Griffin, Matthew; Brachman, David G; Taal, Walter; Rudà, Roberta; Weller, Michael; McBain, Catherine; Reijneveld, Jaap; Enting, Roelien H; Weber, Damien C; Lesimple, Thierry; Clenton, Susan; Gijtenbeek, Anja; Pascoe, Sarah; Herrlinger, Ulrich; Hau, Peter; Dhermain, Frederic; van Heuvel, Irene; Stupp, Roger; Aldape, Ken; Jenkins, Robert B; Dubbink, Hendrikus Jan; Dinjens, Winand N M; Wesseling, Pieter; Nuyens, Sarah; Golfinopoulos, Vassilis; Gorlia, Thierry; Wick, Wolfgang; Kros, Johan M.
Afiliación
  • van den Bent MJ; Neuro-Oncology Unit, Brain Tumour Centre at Erasmus MC Cancer Institute, Rotterdam, Netherlands. Electronic address: m.vandenbent@erasmusmc.nl.
  • Baumert B; Department of Radiation-Oncology (MAASTRO), Maastricht University Medical Centre (MUMC), Maastricht, Netherlands; GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre (MUMC), Maastricht, Netherlands; Department of Radiation-Oncology, University of Münster, Münster
  • Erridge SC; Edinburgh Centre for Neuro-Oncology, Western General Hospital, University of Edinburgh, Edinburgh, UK.
  • Vogelbaum MA; Department of Neurosurgery, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA; Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, OH, USA.
  • Nowak AK; School of Medicine and Pharmacology, University of Western Australia, Crawley, WA, Australia; Co-Operative Group for Neuro-Oncology, University of Sydney, Camperdown, NSW, Australia; Department of Medical Oncology, Sir Charles Gairdner Hospital, Hospital Avenue, Nedlands, WA, Australia.
  • Sanson M; Sorbonne Universités UPMC, University Paris VI, INSERM, CNRS, APHP, Institut du Cerveau et de la Moelle (ICM), Hôpital Pitié-Salpêtrière, F-75013, Paris, France.
  • Brandes AA; Medical Oncology Department, AUSL-IRCCS Scienze Neurologiche, Bologna, Italy.
  • Clement PM; Department of Oncology, KU Leuven, Leuven, Belgium; Department of General Medical Oncology, UZ Leuven, Leuven Cancer Institute, Leuven, Belgium.
  • Baurain JF; Medical Oncology Department, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.
  • Mason WP; Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
  • Wheeler H; Northern Sydney Cancer Centre, North Shore Hospital, St Leonards, NSW, Australia; Department of Medicine, University of Sydney, Sydney, NSW, Australia.
  • Chinot OL; Neuro-Oncology Division, Aix-Marseille University, AP-HM, Marseille, France.
  • Gill S; Department of Medical Oncology, Alfred Hospital, Melbourne, VIC, Australia.
  • Griffin M; Department of Clinical Oncology, Nottingham University Hospitals NHS Trust, Nottingham, UK.
  • Brachman DG; Department of Radiation Oncology, Barrow Neurological Institute, Phoenix, AZ, USA.
  • Taal W; Neuro-Oncology Unit, Brain Tumour Centre at Erasmus MC Cancer Institute, Rotterdam, Netherlands.
  • Rudà R; Department of Neuro-Oncology, City of Health and Science Hospital and University of Turin, Turin, Italy.
  • Weller M; Department of Neurology and Brain Tumour Centre, University Hospital and University of Zurich, Zurich, Switzerland.
  • McBain C; Department of Clinical Oncology, Christie NHS Foundation Trust, Manchester, UK.
  • Reijneveld J; VUmc Cancer Centre Amsterdam, VU University Medical Centre, Amsterdam, Netherlands; Department of Neurology, VU University Medical Centre, Amsterdam, Netherlands; Department of Neurology, Academic Medical Centre, Amsterdam, Netherlands.
  • Enting RH; Department of Neurology, UMCG, University of Groningen, Groningen, Netherlands.
  • Weber DC; Department of Radiation Oncology, University Hospital of Geneva, Geneva, Switzerland.
  • Lesimple T; Department of Clinical Oncology, Comprehensive Cancer Center Eugène Marquis, Rennes, France.
  • Clenton S; Weston Park Hospital, Sheffield, UK.
  • Gijtenbeek A; Department of Neurology, Radboud University Medical Centre, Nijmegen, Netherlands.
  • Pascoe S; Department of Clinical Oncology, Plymouth Hospitals NHS Trust, Plymouth, UK.
  • Herrlinger U; Division of Clinical Neuro-Oncology, Department of Neurology, University of Bonn Medical Centre, Bonn, Germany.
  • Hau P; Wilhelm Sander-Neuro-Oncology Unit and Department of Neurology, University Hospital Regensburg, Regensburg, Germany.
  • Dhermain F; Radiotherapy Department, Gustave Roussy University Hospital, Villejuif, France.
  • van Heuvel I; Neuro-Oncology Unit, Brain Tumour Centre at Erasmus MC Cancer Institute, Rotterdam, Netherlands.
  • Stupp R; Department of Medical Oncology, University Hospital and University of Zurich, Zurich, Switzerland.
  • Aldape K; Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
  • Jenkins RB; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • Dubbink HJ; Department of Pathology, Brain Tumour Centre at Erasmus MC Cancer Institute, Rotterdam, Netherlands.
  • Dinjens WNM; Department of Pathology, Brain Tumour Centre at Erasmus MC Cancer Institute, Rotterdam, Netherlands.
  • Wesseling P; Department of Pathology, VU University Medical Centre, Amsterdam, Netherlands; Department of Pathology, Radboud University Medical Centre, Nijmegen, Netherlands.
  • Nuyens S; EORTC, Brussels, Belgium.
  • Golfinopoulos V; EORTC, Brussels, Belgium.
  • Gorlia T; EORTC, Brussels, Belgium.
  • Wick W; Neurologische Klinik und Nationales Zentrum für Tumorerkrankungen Universitätsklinik, Heidelberg, Germany.
  • Kros JM; Department of Pathology, Brain Tumour Centre at Erasmus MC Cancer Institute, Rotterdam, Netherlands.
Lancet ; 390(10103): 1645-1653, 2017 Oct 07.
Article en En | MEDLINE | ID: mdl-28801186
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Revista: Lancet Año: 2017 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Revista: Lancet Año: 2017 Tipo del documento: Article